Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X MSCI Argentina ETF (ARGT) vs Cassava Sciences Inc (FLNA) Price & Performance

Global X MSCI Argentina ETF
Cassava Sciences Inc

Price performance

Price movement over the last 24 hours

Key statistics

Global X MSCI Argentina ETF vs Cassava Sciences Inc — how do they compare? Global X MSCI Argentina ETF trades at $95.07, while Cassava Sciences Inc trades at $1.18 (market cap $57.49M). The key difference: Global X MSCI Argentina ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

ARGTFLNA
Sector
Broad Market / FactorHealth
52-Week High
$102.94$4.64
52-Week Low
$67.55$1.16
Market Cap
$57.49M
Enterprise Value
-$29.09M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X MSCI Argentina ETF

ARGT (Global X MSCI Argentina ETF) trades at $95.07, up 3.08% with a neutral technical signal. The ETF shows bullish moving averages but mixed oscillators, with support at $92 and resistance at $93. Recent positive sentiment stems from Argentina's economic reforms under the Milei Administration, with Seeking Alpha upgrading the rating to buy citing 28% upside potential based on valuation re-rating opportunities.

The outlook appears constructive given Argentina's improving macroeconomic backdrop, though concentration risk in MercadoLibre and ongoing economic transition pose challenges. Wall Street sentiment has turned positive with institutional accumulation noted, but investors should monitor fiscal stabilization progress and inflation trends for sustained momentum.

Cassava Sciences Inc

FLNA trades at $1.18, down 0.84% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -79.59% and ROA at -62.5%, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights Q1 2026 financial results and scientific presentations on TSC-related epilepsy therapies. Analyst consensus remains positive with 67% buy ratings.

While analyst sentiment is bullish, FLNA faces significant fundamental challenges with negative cash flow and earnings. The primary investment opportunity lies in successful drug development, but risks include sustained cash burn and clinical trial outcomes. Investors should weigh the high-risk biotech profile against potential pipeline catalysts.

Returns comparison

Trailing returns across standard periods

About Global X MSCI Argentina ETF

ARGT seeks to provide investment results that correspond to the performance of the MSCI All Argentina 25/50 Index. It offers targeted exposure to some of the largest and most liquid companies operating in Argentina.

Read more on ARGT

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA